Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In vitro Antibacterial Effect of Reduning Combined with Polymyxin on Carbapenem Resistant .
Infect Drug Resist
January 2025
Department of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, 310012, People's Republic of China.
Objective: This study aimed to investigate the status of carbapenem-resistant strains of isolated from the Department of Microbiology, Zhejiang Tongde Hospital between September 2023 and February 2024, and to examine the in vitro antibacterial effect of Reduning combined with polymyxin on carbapenem-resistant (CRKP), which may provide evidence on the application of Reduning in the clinical anti-infective therapy.
Methods: A total of 50 different isolates of CRKP were collected, and the minimum inhibitory concentrations (MIC) of polymyxin, Reduning and polymyxin plus Reduning were measured with microbroth dilution method. Then, the fractional inhibition concentration index (FICI) was calculated.
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors.
Antimicrob Agents Chemother
January 2025
Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Carbapenemase OXA-48 and its variants pose a serious threat to the development of effective treatments for bacterial infections. OXA-48-producing Enterobacterales are the most prevalent carbapenemase-producing bacteria in large parts of the world. Although these bacteria exhibit low-level carbapenem resistance , the infections they cause are challenging to treat with conventional therapies, owing to their spread and complex detection in clinical settings.
View Article and Find Full Text PDFAntimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global Surveillance.
J Pediatric Infect Dis Soc
January 2025
IHMA, Schaumburg, Illinois, USA.
Objectives: To evaluate the in vitro susceptibility of recent Gram-negative pathogens collected from pediatric patients to imipenem/relebactam (IMI/REL) and comparator agents.
Methods: From 2018 to 2022 254 hospitals in 62 countries collected Enterobacterales or Pseudomonas aeruginosa isolates from patients <18 years old as part of the SMART global surveillance program. Minimum inhibitory concentrations (MIC)s were determined using CLSI broth microdilution and interpreted with 2024 CLSI breakpoints.
The Virulence Gene and Drug Resistance Analysis of Shiga Toxin-Producing from Diarrhea Calves in Xinjiang, China.
Foodborne Pathog Dis
January 2025
College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, China.
This investigation aimed to examine the virulence genes and antimicrobial resistance profiles of Shiga toxin-producing (STEC) strains found in diarrheal calves in Xinjiang between 2016 and 2022. A total of 800 samples, including 232 fecal and 568 rectal swabs from calves under 2 months old with diarrhea, were analyzed for Shiga toxin (Stx)-encoding genes using polymerase chain reaction. The study characterized the isolates based on their subtypes, virulence genes, O serogroups, phylogenetic groups, hemolytic phenotypes, antibiotic resistance, and resistance genes.
View Article and Find Full Text PDFResponse Surface D-Optimal Design for Optimizing Fortimicins Production by Micromonospora olivasterospora and New Synergistic Fortimicin-A-Antibiotic Combinations.
Curr Microbiol
January 2025
Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Fortimicins (FTMs) are fortamine-containing aminoglycoside antibiotics (AGAs) produced by M. olivasterospora DSM 43868 with excellent bactericidal activities against a wide range of Enterobacteriaceae and synergistic activity against multidrug-resistant (MDR) pathogens. Fortimicin-A (FTM-A), the most active member of FTMs, has the lowest susceptibility to inactivation by the aminoglycoside modifying enzymes (AMEs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!